Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Canada's Acasti Signs $133 Million Non-Binding Term Sheet with China Pharma

publication date: Nov 20, 2017

Canada's Acasti Pharma signed a $133 million non-binding term sheet with an unnamed China pharma for China/Asia rights to its hypertriglyceridemia drug candidate. CaPre, a prescription medication, is a highly concentrated omega-3 phospholipid derived from krill. Acasti believes CaPre is more readily absorbed into the body than competing omega-3 products. Earlier this year, Acasti announced Phase III trials of the candidate, which will use the abbreviated 505(b)(2) pathway for approval in the US. More details....

Stock Symbol: (NSDQ/TSX: ACST)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital